Article Text

Download PDFPDF
Age-related macular degeneration and recent developments: new hope for old eyes?
  1. Brid Morris,
  2. Fraser Imrie,
  3. Ana-Maria Armbrecht,
  4. Baljean Dhillon
  1. Princess Alexandra Eye Pavilion, Edinburgh, UK
  1. Correspondence to:
 Dr Brid Morris
 Princess Alexandra Eye Pavilion, Chalmers St., Edinburgh EH3 9HA, UK;bridcmorris{at}


Age-related macular degeneration (AMD) is the commonest cause of blindness in the population over 60 years of age and accounts for over 50% of those registered blind in the UK. The incidence is increasing and as older generations live longer a growing number of patients will be affected in the future. Affected patients lose central vision, important in all aspects of everyday life. This review outlines risk factors for AMD, clinical features, treatment and management strategies for patients, families and physicians caring for those with AMD. Recent trials are included along with practical clinical advice. While there is no curative treatment at present, intervention can reduce the risk of developing AMD and limit disease progression if it occurs. These modalities are discussed here. As new discoveries in the field of genetics and novel therapies emerge, a brighter future seems certain for the ageing population.

  • AMD, age-related macular degeneration
  • CNV, choroidal neovascular membrane
  • IOL, intraocular lens
  • PDT, photodynamic therapy
  • RNIB, Royal National Institute for the Blind
  • VEGF, vascular endothelial derived growth factor
  • age-related macular degeneration
  • blindness
  • choroidal neovascular membrane
  • elderly
  • photodynamic therapy
  • quality of life
View Full Text

Statistics from


  • Funding: None.

  • Competing interests: None.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.